GeneDx Holdings Corp.
Last updated September 27, 2026
Organization details
- Legal name
- GeneDx Holdings Corp.
- Ownership
- Public
- Status
- Active
- Headquarters country
- United States
- Ticker symbol
- WGS
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0001818331
Board of directors
-
Eli Casdin · DirectorSince 2023
-
Emily M. Leproust · DirectorSince 2023
-
Jason Ryan · DirectorSince 2023
-
Joshua Ruch · DirectorSince 2023
-
Katherine Stueland · Director · CHIEF EXECUTIVE OFFICERSince 2023
-
Keith A. Meister · DirectorSince 2023
-
Rachel E. Sherman · DirectorSince 2023
-
Richard C. Pfenniger Jr. · DirectorSince 2023
-
Thomas Fuchs · DirectorSince 2025
Chief executives
Katherine Stueland
· Chief Executive Officer
Dates unknown
Board connections
4 of this board's directors also sit on 8 other boards.
- via Richard C. Pfenniger Jr.
- via Richard C. Pfenniger Jr.
- via Keith A. Meister
- via Keith A. Meister
- via Richard C. Pfenniger Jr.
- via Eli Casdin
- via Emily M. Leproust
- via Keith A. Meister
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $106,601,813
- 34 purchases by 3 insiders
- Sold, last 12 months
- $23,917,338
- 123 sales by 4 insiders
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Sep 17, 2026 | Thomas Fuchs Director | Option exercise | +1,146 | — | — |
| Sep 16, 2026 | Feeley Kevin Officer (CHIEF FINANCIAL OFFICER) | Option exercise | +7,197 | — | — |
| Sep 16, 2026 | Katherine Stueland Director, Officer (CHIEF EXECUTIVE OFFICER) | Option exercise | +18,750 | — | — |
| Sep 16, 2026 | Feeley Kevin Officer (CHIEF FINANCIAL OFFICER) | Open-market sale | −586 | $94.26 | $55,235 |
| Sep 16, 2026 | Katherine Stueland Director, Officer (CHIEF EXECUTIVE OFFICER) | Open-market sale | −1,648 | $94.26 | $155,337 |
| Sep 16, 2026 | Feeley Kevin Officer (CHIEF FINANCIAL OFFICER) | Open-market sale | −52 | $95.41 | $4,961 |
| Sep 16, 2026 | Katherine Stueland Director, Officer (CHIEF EXECUTIVE OFFICER) | Open-market sale | −148 | $95.41 | $14,120 |
| Sep 16, 2026 | Feeley Kevin Officer (CHIEF FINANCIAL OFFICER) | Open-market sale | −541 | $96.90 | $52,423 |
| Sep 16, 2026 | Katherine Stueland Director, Officer (CHIEF EXECUTIVE OFFICER) | Open-market sale | −1,525 | $96.90 | $147,774 |
| Sep 16, 2026 | Feeley Kevin Officer (CHIEF FINANCIAL OFFICER) | Open-market sale | −1,470 | $98.27 | $144,457 |
| Sep 16, 2026 | Katherine Stueland Director, Officer (CHIEF EXECUTIVE OFFICER) | Open-market sale | −4,141 | $98.27 | $406,936 |
| Sep 16, 2026 | Feeley Kevin Officer (CHIEF FINANCIAL OFFICER) | Open-market sale | −1,079 | $99.00 | $106,816 |
| Sep 16, 2026 | Katherine Stueland Director, Officer (CHIEF EXECUTIVE OFFICER) | Open-market sale | −3,039 | $99.00 | $300,846 |
| Sep 9, 2026 | Feeley Kevin Officer (CHIEF FINANCIAL OFFICER) | Option exercise | +2,462 | — | — |
| Sep 9, 2026 | Katherine Stueland Director, Officer (CHIEF EXECUTIVE OFFICER) | Option exercise | +6,547 | — | — |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.